Displaying drugs 176 - 200 of 407 in total
| Name | Weight | Structure | Desription | Categories |
|---|---|---|---|---|
| Blinatumomab | 54100.0 C2367H3577N649O772S19 |  | An antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD). | Antibodies, Monoclonal |
| Efgartigimod alfa | 54000.0 |  | A neonatal Fc receptor blocker used to treat generalized myasthenia gravis in patients who are AChR-antibody positive. | Selective Immunosuppressants |
| Hyaluronidase (ovine) | 53870.9 C2455H3775N617O704S21 |  | A purified form of sheep hyaluronidase enzyme used as an adjunct in subcutaneous rehydration therapy and to increase absorption of other drugs and radiopaque imaging agents. | Enzymes |
| Alefacept | 51801.1 C2306H3594N610O694S26 |  | A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. | Selective Immunosuppressants |
| Etanercept | 51234.9 C2224H3475N621O698S36 |  | A protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis. | Tumor necrosis factor alpha (TNF-alpha) inhibitors |
| Ranibizumab | 48349.6111 C2158H3282N562O681S12 |  | A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. | Antineovascularisation Agents |
| Pancrelipase lipase | 48000.0 |  | A lipase used to treat pancreatic exocrine insufficiency. | Carboxylic Ester Hydrolases / Lipase |
| Digoxin Immune Fab (Ovine) | 47301.7 C2085H3223N553O672S16 |  | An antibody binding fragment which binds digoxin molecules which is used as an antidote to digoxin overdose. | Antidotes / Immunoglobulin G |
| Streptokinase | 47286.7 C2100H3278N566O669S4 |  | A purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism. | Enzymes |
| Coagulation Factor IX (Recombinant) | 46548.2 C2041H3136N558O641S25 |  | A form of recombinant human coagulation Factor IX used to treat hemophilia B. | Blood Coagulation Factors |
| Coagulation Factor IX Human | 46548.2 C2041H3136N558O641S25 |  | A coagulation factor used to treat hemophilia B or factor IX hemophilia. | Blood Coagulation Factors / Enzyme Precursors / Factor IX |
| Agalsidase beta | 45351.6 C2029H3080N544O587S27 |  | A recombinant human alpha-galactosidase indicated to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide. | Enzymes / Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme |
| Agalsidase alfa | 45351.6 C2029H3080N544O587S27 |  | A recombinant human alpha-galactosidase indicated to treat Fabry disease, a genetic deficiency in the enzyme leading to buildup of globotriaosylceramide. | alpha-Galactosidase, antagonists & inhibitors / Enzymes / Galactosidases |
| Coagulation factor VIIa Recombinant Human | 45079.1 C1972H3076N560O597S28 |  | A form of recombinant human coagulation Factor VII used to treat hemophilia A and B. | Blood Coagulation Factors / Factor VII / Factor VIIa, antagonists & inhibitors / Serine Endopeptidases |
| Alpha-1-proteinase inhibitor | 44324.5 C2001H3130N514O601S10 |  | A purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency. | Proteinase Inhibitors |
| Pegademase | 40788.2 C1821H2834N484O552S14 |  | A modified form of bovine adenosine deaminase used to treat adenosine deaminase deficiency, a condition which leads to the formation of adenosine metabolites which are cytotoxic to lymphocytes. | Bovine Intestinal Adenosine Deaminase / Severe Combined Immunodeficiency |
| Human interferon beta | 40036.0 | | A polypeptide drug used in the treatment of relapsing forms of Multiple Sclerosis (MS). | Immunologic Factors / Interferon Type I |
| Reteplase | 39589.6 C1736H2671N499O522S22 |  | A purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. | Enzymes |
| Pegfilgrastim | 39000.0 C845H1343N223O243S9 |  | A recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy. | Colony-Stimulating Factors |
| Lipegfilgrastim | 39000.0 C866H1372N226O258S9*(C2H4O)n |  | A medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy. | Colony-Stimulating Factors |
| Pegloticase | 34192.8533 C1549H2430N408O448S8 | | A recombinant uricase used for the treatment of chronic gout in adult patients refractory to conventional therapy. | Uric Acid-specific Enzyme |
| Rasburicase | 34109.5 C1521H2381N417O461S7 |  | A recombinant form of urate-oxidase enzyme used to treat hyperuricemia following chemotherapy for leukemias and non-Hodgkin's lymphoma. | Detoxifying Agents for Antineoplastic Treatment |
| Pegaspargase | 31731.9 C1377H2208N382O442S17 |  | A modified form of L-asparagine amidohydrolase used to treat acute lymphoblastic leukemia, which is dependent on an external source of asparagine. | Asparagine-specific Enzyme / Delayed-Action Preparations |
| Urokinase | 31126.5 C1376H2145N383O406S18 |  | A low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines. | Enzymes |
| Peginterferon alfa-2b | 31000.0 |  | A purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers. | Antiviral Agents / Drug Carriers / Hepatitis C / Interferon alpha / Interferons |
Displaying drugs 176 - 200 of 407 in total